{"id":"lxi-15028","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SGLT2 inhibitors like LXI-15028 work by blocking the reabsorption of glucose in the kidneys, thereby reducing blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes. LXI-15028's SGLT2 inhibition leads to increased glucose excretion in the urine, which helps to lower blood glucose levels.","oneSentence":"LXI-15028 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:51.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05883306","phase":"PHASE1","title":"Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2022-06-30","conditions":"Healthy Subjects, Pharmacokinetics of 14C-labeled of LXI-15028","enrollment":6},{"nctId":"NCT05010954","phase":"PHASE3","title":"Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2021-10-18","conditions":"Duodenal Ulcer","enrollment":400},{"nctId":"NCT03615677","phase":"PHASE3","title":"Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2018-10-24","conditions":"Erosive Esophagitis (EE)","enrollment":261},{"nctId":"NCT03591653","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2018-10-29","conditions":"Non-erosive Reflux Disease","enrollment":291},{"nctId":"NCT03458650","phase":"PHASE1","title":"A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2018-03-19","conditions":"Healthy","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LXI-15028","genericName":"LXI-15028","companyName":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","companyId":"shandong-luoxin-pharmaceutical-group-stock-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LXI-15028 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}